Inhibition of GSK-3β may inhibit tumor growth and improve survival through several complimentary mechanisms that include enhancement of chemotherapy activity, activation of innate anti-tumor immunity, ...

Avance Clinical, the award-winning, global CRO for biotechs, is proud to announce its sponsorship of the Citeline Awards 2025 ...

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become ...

DNLI reports a wider-than-expected loss for the first quarter of 2025. Denali submits a BLA for tividenofusp alfa under the ...

Companies across the stakeholder spread are investing in AI to ease some of the longstanding operational challenges—but new ...

Any novel candidate therapeutic developed in this program will be co-owned and co-prosecuted by BioVaxys and Sona, with the parties planning to enter into a commercialization agreement for a vaccine ...

TScan Therapeutics, Inc.’s TCRX share price has surged by 5.15%, which has investors questioning if this is right time to ...

Galectin Therapeutics Inc.’s GALT share price has surged by 14.71%, which has investors questioning if this is right time to ...

A groundbreaking trial found vagus nerve stimulation combined with therapy may fully eliminate PTSD symptoms in patients.

Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) ("Sona") announce today that they have entered into a Research Agreement ...